+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Gout Therapeutics Market - Global Forecast 2026-2032- Product Image
Gout Therapeutics Market - Global Forecast 2026-2032- Product Image
Sale

Gout Therapeutics Market - Global Forecast 2026-2032

  • Report

  • 193 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 4904565
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Gout Therapeutics Market is projected to reach USD 3.80 Billion in 2026. It is expected to continue growing at a CAGR of 11.47%, reaching USD 7.36 Billion by 2032.

Gout therapeutics address one of the most common forms of inflammatory arthritis, driven by monosodium urate crystal deposition following sustained hyperuricemia. The treatment landscape spans acute flare control with NSAIDs, colchicine, corticosteroids, and selected IL-1 inhibition, alongside long-term urate-lowering therapy with xanthine oxidase inhibitors, uricosurics, and biologic options for refractory or tophaceous disease.

Clinical practice has moved toward treat-to-target serum urate management, commonly below 6 mg/dL and below 5 mg/dL in selected severe cases, as reflected in major rheumatology guidelines. Demand is reinforced by aging populations, chronic kidney disease, obesity, hypertension, diabetes, diuretic use, and rising recognition that gout is a chronic, controllable disease rather than an episodic pain condition requiring only short-term relief.

Transformative Shifts in the Gout Therapeutics Landscape

The gout treatment landscape is shifting from flare-centered prescribing to long-term disease modification. Allopurinol remains the guideline-preferred first-line urate-lowering therapy for most patients, while febuxostat, probenecid, pegloticase, and anti-inflammatory prophylaxis are positioned according to renal function, cardiovascular risk, tophi burden, medication tolerance, and prior treatment response.

Transformative momentum is also coming from precision medicine, adherence programs, and evidence supporting immunomodulator co-therapy with pegloticase in uncontrolled gout to improve sustained urate-lowering response and reduce immunogenicity. Safety monitoring, HLA-B*58:01 testing in high-risk ancestry groups, renal-dose optimization, patient-reported outcome tracking, and real-world outcomes evidence are becoming central to clinical differentiation and payer confidence.

Cumulative Impact of Artificial Intelligence on Gout Care

Artificial intelligence is beginning to influence gout therapeutics through earlier detection, risk stratification, and more efficient care pathways. EHR-based models can flag patients with recurrent flares, elevated serum urate, chronic kidney disease, obesity, cardiovascular comorbidities, or diuretic exposure, enabling timely initiation, titration, and monitoring of urate-lowering therapy.

AI also supports imaging interpretation in ultrasound and dual-energy CT, clinical trial matching, pharmacovigilance signal detection, medication persistence monitoring, and patient adherence analytics. Its value depends on transparent validation, representative datasets, privacy safeguards, physician oversight, and alignment with established diagnostic and treatment standards to avoid bias and overdiagnosis.

Key Regional Insights Across Global Gout Therapeutics

Asia-Pacific is gaining strategic importance as China, India, Japan, South Korea, and Australia manage a rising gout burden linked to aging, urban diets, alcohol and purine-rich food exposure, renal disease, and metabolic syndrome. North America remains a mature gout therapeutics environment with high diagnosis rates, established rheumatology and primary care infrastructure, strong laboratory monitoring capacity, and broader uptake of advanced therapies for uncontrolled or tophaceous gout.

Latin America shows growing demand for gout treatment, but access remains uneven due to variation in specialist availability, diagnostic testing, reimbursement, and biologic therapy affordability. Europe benefits from guideline-led care, health technology assessment, structured reimbursement evaluation, and strong pharmacovigilance systems that support evidence-based prescribing. The Middle East faces elevated cardiometabolic risk, particularly in Gulf health systems with high diabetes, obesity, and chronic kidney disease prevalence, while Africa remains underdiagnosed, with gout therapeutics access shaped by affordability, laboratory capacity, essential medicine availability, and primary care awareness.

Key Group Insights for Gout Therapeutics Adoption

ASEAN markets show expanding need for affordable urate-lowering therapy as urbanization, dietary transition, diabetes, obesity, and kidney disease increase gout risk, although diagnosis, serum urate monitoring, and specialist access vary widely across health systems. The GCC is shaped by high cardiometabolic disease prevalence, including obesity, diabetes, hypertension, and chronic kidney disease, creating strong need for integrated metabolic, nephrology, cardiology, and rheumatology care pathways.

The European Union emphasizes evidence-based prescribing, reimbursement scrutiny, pharmacovigilance, and clinical guideline alignment, supporting structured use of both established urate-lowering medicines and selected advanced therapies. BRICS countries combine large patient populations with strong demand for generics, scalable primary care models, and improved diagnosis in underserved settings. G7 markets lead in innovation adoption, biologics access, real-world evidence generation, and digital health integration, while NATO member countries benefit from overlapping advanced health infrastructure, coordinated regulatory standards in many member states, and resilient pharmaceutical supply priorities.

Key Country Insights in Gout Therapeutics

The United States has one of the best-documented gout burdens, with NHANES analyses estimating prevalence near 3.9% of adults, supporting strong demand for treat-to-target care, specialty management of uncontrolled gout, and adherence-focused programs. Canada, the United Kingdom, Germany, France, Italy, and Spain rely on mature guideline frameworks, laboratory monitoring, and established reimbursement pathways, while Russia, Mexico, and Brazil show opportunities tied to broader diagnosis, primary care education, and access to affordable urate-lowering medicines.

China and India represent high-volume gout therapeutics settings shaped by population scale, diet transition, rising metabolic disease, renal disease, and expanding specialty care networks. Japan, South Korea, and Australia combine aging demographics with strong clinical awareness, pharmacovigilance, guideline adoption, and interest in personalized safety strategies such as HLA-B*58:01 risk assessment in populations with higher allele prevalence and greater risk of severe cutaneous adverse reactions to allopurinol.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize treat-to-target solutions that combine urate-lowering therapy, flare prophylaxis, patient education, serum urate monitoring, and adherence support. Evidence-based dose titration, renal and cardiovascular risk assessment, drug interaction review, and safety screening can improve outcomes while reducing avoidable flares, emergency visits, joint damage, and tophi progression.

Commercial and access strategies should align with local reimbursement realities, generic competition, formulary requirements, and specialist capacity. Leaders can strengthen differentiation through real-world evidence, AI-enabled patient identification, specialty pharmacy support for refractory gout, culturally relevant adherence tools, and partnerships across nephrology, cardiology, endocrinology, rheumatology, and primary care networks.

Research Methodology

This executive summary is built on a structured review of verified clinical, regulatory, epidemiological, and market-relevant sources, including rheumatology guidelines, approved drug labels, clinical trial publications, public health datasets, pharmacovigilance references, and peer-reviewed gout burden studies. Insights were triangulated across treatment class, patient pathway, disease severity, comorbidity burden, region, payer environment, and access conditions.

The methodology emphasizes data-backed interpretation rather than speculative forecasting. Findings were assessed for consistency with established evidence on hyperuricemia management, acute flare control, chronic urate lowering, tophaceous gout, safety monitoring, access barriers, adherence challenges, and emerging digital health applications in diagnosis, monitoring, and care coordination.

Conclusion

Gout therapeutics are entering a more disciplined era defined by chronic disease control, precision safety, adherence improvement, and targeted use of advanced therapies. The field remains anchored by proven urate-lowering medicines, but unmet need persists in uncontrolled gout, delayed diagnosis, undertreatment, recurrent flares, tophi, comorbidity complexity, and poor long-term medication persistence.

Organizations that combine scientific credibility, evidence generation, AI-enabled care support, safety-focused personalization, and region-specific access strategies will be best positioned to improve patient outcomes and build durable leadership in gout treatment.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.1.1. Expanding Global Disease Burden
4.3.1.2. More Active Treat-to-Target Management
4.3.1.3. Established Value of Advanced Biologic Therapy
4.3.1.4. Pipeline Progress and Regional Product Innovation
4.3.2. Key Restraints
4.3.2.1. Entrenched, Low-Cost Initial Therapy Limits Premium Switching
4.3.2.2. Safety Labeling and Comorbidities Narrow Addressable Use
4.3.2.3. Reimbursement and Site-of-Care Friction Constrain Adoption
4.3.2.4. Treatment Inertia and Persistence Gaps Reduce Realized Demand
4.3.3. Key Opportunities
4.3.3.1. Integrated Pathways for Uncontrolled and Refractory Gout
4.3.3.2. Differentiated Oral Therapy After Inadequate Control
4.3.3.3. Targeted Therapies for Difficult-to-Treat Acute Flares
4.3.3.4. Localized Innovation and Commercialization in Asia-Pacific
4.3.4. Key Challenges
4.3.4.1. Converting Clinical Results Into Defensible Differentiation
4.3.4.2. Turning Authorization Into Reimbursed Patient Starts
4.3.4.3. Maintaining Resilient Supply and Delivery Infrastructure
4.3.4.4. Executing Acquisitions and Territorial Partnerships
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Gout Therapeutics Market, by Therapeutic Technology
7.1. Introduction
7.2. Small-Molecule Therapies
7.2.1. Direct-Acting Single-Active Therapies
7.2.1.1. Xanthine Oxidase Inhibitors
7.2.1.2. Microtubule-Modulating Agents
7.2.1.3. Uricosuric Agents
7.2.1.4. Nonsteroidal Anti-inflammatory Drugs
7.2.1.5. Corticosteroid Anti-inflammatory Agents
7.2.1.6. NLRP3 Inflammasome Inhibitors
7.2.2. Treatment-Enabling Co-Therapies
7.2.3. Fixed-Combination Therapies
7.3. Biologic and Protein Therapies
7.3.1. Recombinant Uricase Therapies
7.3.2. Interleukin-1 Pathway Inhibitors
8. Gout Therapeutics Market, by Treatment Line
8.1. Introduction
8.2. Advanced Uncontrolled or Refractory Therapy
8.3. Initial Standard Therapy
8.4. Alternative or Add-On Therapy
9. Gout Therapeutics Market, by Therapeutic Role
9.1. Introduction
9.2. Sustained Urate Reduction and Crystal-Deposit Resolution
9.3. Acute Flare Control
9.4. Flare Prophylaxis
10. Gout Therapeutics Market, by Administration Route
10.1. Introduction
10.2. Oral Administration
10.3. Parenteral Administration
10.3.1. Intravenous Administration
10.3.2. Subcutaneous Administration
10.3.3. Intra-articular Administration
10.3.4. Intramuscular Administration
11. Gout Therapeutics Market, by Dispensing and Procurement Channel
11.1. Introduction
11.2. Pharmacy Dispensing
11.2.1. Community and Retail Pharmacy
11.2.2. Mail-Order Pharmacy
11.2.3. Specialty Pharmacy
11.3. Provider & Institutional Procurement
12. Gout Therapeutics Market, by Asset Status
12.1. Introduction
12.2. Commercially Authorized Assets
12.2.1. Originator and Proprietary Products
12.2.2. Generic Products
12.3. Phase I Clinical Assets
12.4. Phase II Clinical Assets
12.5. Phase III Clinical Assets
12.6. Regulatory Review Assets
13. Gout Therapeutics Market, by Region
13.1. Introduction
13.2. North America
13.3. Europe
13.4. Asia-Pacific
13.5. Latin America
13.6. Middle East
13.7. Africa
14. Gout Therapeutics Market, by Group
14.1. Introduction
14.2. NATO
14.3. G7
14.4. European Union
14.5. BRICS
14.6. ASEAN
14.7. GCC
15. Gout Therapeutics Market, by Country
15.1. Introduction
15.2. United States
15.3. Japan
15.4. China
15.5. Germany
15.6. United Kingdom
15.7. France
15.8. Italy
15.9. Canada
15.10. Spain
15.11. South Korea
15.12. Brazil
15.13. Russia
15.14. India
15.15. Australia
15.16. Mexico
16. Competitive Landscape
16.1. Market Share Analysis, 2025
16.2. Market Concentration Analysis, 2025
16.2.1. Concentration Ratio (CR)
16.2.2. Herfindahl Hirschman Index (HHI)
16.3. Recent Developments & Impact Analysis, 2025
16.4. Product Portfolio Analysis, 2025
16.5. Benchmarking Analysis, 2025
17. Company Profiles
17.1. Amgen Inc.
17.2. Takeda Pharmaceutical Company Limited
17.3. Teijin Pharma Limited
17.4. Menarini Group
17.5. Fuji Yakuhin Co., Ltd.
17.6. Eisai Co., Ltd.
17.7. Novartis AG
17.8. Hikma Pharmaceuticals PLC
17.9. Scilex Holding Company
17.10. Swedish Orphan Biovitrum AB
17.11. LG Chem, Ltd.
17.12. JW Pharmaceutical
17.13. Crystalys Therapeutics, Inc.
17.14. Sun Pharmaceutical Industries Limited
17.15. Aurobindo Pharma Limited
17.16. Dr. Reddy's Laboratories Limited
17.17. Innovent Biologics, Inc.
17.18. Atom Therapeutics Co., Ltd.
17.19. Shanton Pharma Holdings Limited
17.20. Sanwa Kagaku Kenkyusho Co., Ltd.
17.21. TOA EIYO LTD.
17.22. Mochida Pharmaceutical Co., Ltd.
17.23. Kaken Pharmaceutical Co., Ltd.
17.24. Viatris Inc.
17.25. Apotex Inc.
17.26. Rising Pharma Holdings, Inc.
17.27. Alembic Pharmaceuticals Limited
17.28. KRKA, d. d., Novo mesto
17.29. Laboratoires Mayoly Spindler
17.30. Jiangsu Hengrui Pharmaceuticals Co., Ltd.
17.31. Protalix BioTherapeutics, Inc.
17.32. Olatec Therapeutics LLC
17.33. 3SBio Inc.
17.34. Changchun GeneScience Pharmaceutical Co., Ltd.
17.35. BioRay Biopharmaceutical Co., Ltd.
17.36. China Medical System Holdings Limited
17.37. Shanghai Institute of Biological Products Co., Ltd.
17.38. Innorna Co., Ltd.
17.39. ANI Pharmaceuticals, Inc.
18. Key Experts
List of Figures
FIGURE 1. Global Gout Therapeutics Market, Years Considered for the Study
FIGURE 2. Global Gout Therapeutics Market, Research Design
FIGURE 3. Global Gout Therapeutics Market, Research Framework
FIGURE 4. Global Gout Therapeutics Market, Data Triangulation
FIGURE 5. Global Gout Therapeutics Market Size, 2017-2032 (USD Million)
FIGURE 6. Global Gout Therapeutics Market Size, by Therapeutic Technology, 2025 vs 2032 (%)
FIGURE 7. Global Gout Therapeutics Market Size, by Therapeutic Technology, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global Gout Therapeutics Market Size, by Treatment Line, 2025 vs 2032 (%)
FIGURE 9. Global Gout Therapeutics Market Size, by Treatment Line, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global Gout Therapeutics Market Size, by Therapeutic Role, 2025 vs 2032 (%)
FIGURE 11. Global Gout Therapeutics Market Size, by Therapeutic Role, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global Gout Therapeutics Market Size, by Administration Route, 2025 vs 2032 (%)
FIGURE 13. Global Gout Therapeutics Market Size, by Administration Route, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global Gout Therapeutics Market Size, by Dispensing and Procurement Channel, 2025 vs 2032 (%)
FIGURE 15. Global Gout Therapeutics Market Size, by Dispensing and Procurement Channel, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global Gout Therapeutics Market Size, by Asset Status, 2025 vs 2032 (%)
FIGURE 17. Global Gout Therapeutics Market Size, by Asset Status, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 18. Global Gout Therapeutics Market Size, by Region, 2025 vs 2032 (%)
FIGURE 19. Global Gout Therapeutics Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 20. Global Gout Therapeutics Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 21. Global Gout Therapeutics Market Size, by Country, 2025 vs 2032 (%)
FIGURE 22. Global Gout Therapeutics Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 23. Global Gout Therapeutics Market Share, by Key Player, 2025
List of Tables
TABLE 1. Global Gout Therapeutics Market Segmentation & Coverage
TABLE 2. Global Gout Therapeutics Market Size, 2017-2032 (USD Million)
TABLE 3. Global Gout Therapeutics Market Size, by Therapeutic Technology, 2017-2032 (USD Million)
TABLE 4. Global Small-Molecule Therapies Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Small-Molecule Therapies Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Small-Molecule Therapies Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global Direct-Acting Single-Active Therapies Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global Direct-Acting Single-Active Therapies Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global Direct-Acting Single-Active Therapies Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Xanthine Oxidase Inhibitors Market Size, by Region, 2017-2032 (USD Million)
TABLE 11. Global Xanthine Oxidase Inhibitors Market Size, by Group, 2017-2032 (USD Million)
TABLE 12. Global Xanthine Oxidase Inhibitors Market Size, by Country, 2017-2032 (USD Million)
TABLE 13. Global Microtubule-Modulating Agents Market Size, by Region, 2017-2032 (USD Million)
TABLE 14. Global Microtubule-Modulating Agents Market Size, by Group, 2017-2032 (USD Million)
TABLE 15. Global Microtubule-Modulating Agents Market Size, by Country, 2017-2032 (USD Million)
TABLE 16. Global Uricosuric Agents Market Size, by Region, 2017-2032 (USD Million)
TABLE 17. Global Uricosuric Agents Market Size, by Group, 2017-2032 (USD Million)
TABLE 18. Global Uricosuric Agents Market Size, by Country, 2017-2032 (USD Million)
TABLE 19. Global Nonsteroidal Anti-inflammatory Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 20. Global Nonsteroidal Anti-inflammatory Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 21. Global Nonsteroidal Anti-inflammatory Drugs Market Size, by Country, 2017-2032 (USD Million)
TABLE 22. Global Corticosteroid Anti-inflammatory Agents Market Size, by Region, 2017-2032 (USD Million)
TABLE 23. Global Corticosteroid Anti-inflammatory Agents Market Size, by Group, 2017-2032 (USD Million)
TABLE 24. Global Corticosteroid Anti-inflammatory Agents Market Size, by Country, 2017-2032 (USD Million)
TABLE 25. Global NLRP3 Inflammasome Inhibitors Market Size, by Region, 2017-2032 (USD Million)
TABLE 26. Global NLRP3 Inflammasome Inhibitors Market Size, by Group, 2017-2032 (USD Million)
TABLE 27. Global NLRP3 Inflammasome Inhibitors Market Size, by Country, 2017-2032 (USD Million)
TABLE 28. Global Treatment-Enabling Co-Therapies Market Size, by Region, 2017-2032 (USD Million)
TABLE 29. Global Treatment-Enabling Co-Therapies Market Size, by Group, 2017-2032 (USD Million)
TABLE 30. Global Treatment-Enabling Co-Therapies Market Size, by Country, 2017-2032 (USD Million)
TABLE 31. Global Fixed-Combination Therapies Market Size, by Region, 2017-2032 (USD Million)
TABLE 32. Global Fixed-Combination Therapies Market Size, by Group, 2017-2032 (USD Million)
TABLE 33. Global Fixed-Combination Therapies Market Size, by Country, 2017-2032 (USD Million)
TABLE 34. Global Biologic and Protein Therapies Market Size, by Region, 2017-2032 (USD Million)
TABLE 35. Global Biologic and Protein Therapies Market Size, by Group, 2017-2032 (USD Million)
TABLE 36. Global Biologic and Protein Therapies Market Size, by Country, 2017-2032 (USD Million)
TABLE 37. Global Recombinant Uricase Therapies Market Size, by Region, 2017-2032 (USD Million)
TABLE 38. Global Recombinant Uricase Therapies Market Size, by Group, 2017-2032 (USD Million)
TABLE 39. Global Recombinant Uricase Therapies Market Size, by Country, 2017-2032 (USD Million)
TABLE 40. Global Interleukin-1 Pathway Inhibitors Market Size, by Region, 2017-2032 (USD Million)
TABLE 41. Global Interleukin-1 Pathway Inhibitors Market Size, by Group, 2017-2032 (USD Million)
TABLE 42. Global Interleukin-1 Pathway Inhibitors Market Size, by Country, 2017-2032 (USD Million)
TABLE 43. Global Gout Therapeutics Market Size, by Treatment Line, 2017-2032 (USD Million)
TABLE 44. Global Advanced Uncontrolled or Refractory Therapy Market Size, by Region, 2017-2032 (USD Million)
TABLE 45. Global Advanced Uncontrolled or Refractory Therapy Market Size, by Group, 2017-2032 (USD Million)
TABLE 46. Global Advanced Uncontrolled or Refractory Therapy Market Size, by Country, 2017-2032 (USD Million)
TABLE 47. Global Initial Standard Therapy Market Size, by Region, 2017-2032 (USD Million)
TABLE 48. Global Initial Standard Therapy Market Size, by Group, 2017-2032 (USD Million)
TABLE 49. Global Initial Standard Therapy Market Size, by Country, 2017-2032 (USD Million)
TABLE 50. Global Alternative or Add-On Therapy Market Size, by Region, 2017-2032 (USD Million)
TABLE 51. Global Alternative or Add-On Therapy Market Size, by Group, 2017-2032 (USD Million)
TABLE 52. Global Alternative or Add-On Therapy Market Size, by Country, 2017-2032 (USD Million)
TABLE 53. Global Gout Therapeutics Market Size, by Therapeutic Role, 2017-2032 (USD Million)
TABLE 54. Global Sustained Urate Reduction and Crystal-Deposit Resolution Market Size, by Region, 2017-2032 (USD Million)
TABLE 55. Global Sustained Urate Reduction and Crystal-Deposit Resolution Market Size, by Group, 2017-2032 (USD Million)
TABLE 56. Global Sustained Urate Reduction and Crystal-Deposit Resolution Market Size, by Country, 2017-2032 (USD Million)
TABLE 57. Global Acute Flare Control Market Size, by Region, 2017-2032 (USD Million)
TABLE 58. Global Acute Flare Control Market Size, by Group, 2017-2032 (USD Million)
TABLE 59. Global Acute Flare Control Market Size, by Country, 2017-2032 (USD Million)
TABLE 60. Global Flare Prophylaxis Market Size, by Region, 2017-2032 (USD Million)
TABLE 61. Global Flare Prophylaxis Market Size, by Group, 2017-2032 (USD Million)
TABLE 62. Global Flare Prophylaxis Market Size, by Country, 2017-2032 (USD Million)
TABLE 63. Global Gout Therapeutics Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 64. Global Oral Administration Market Size, by Region, 2017-2032 (USD Million)
TABLE 65. Global Oral Administration Market Size, by Group, 2017-2032 (USD Million)
TABLE 66. Global Oral Administration Market Size, by Country, 2017-2032 (USD Million)
TABLE 67. Global Parenteral Administration Market Size, by Region, 2017-2032 (USD Million)
TABLE 68. Global Parenteral Administration Market Size, by Group, 2017-2032 (USD Million)
TABLE 69. Global Parenteral Administration Market Size, by Country, 2017-2032 (USD Million)
TABLE 70. Global Intravenous Administration Market Size, by Region, 2017-2032 (USD Million)
TABLE 71. Global Intravenous Administration Market Size, by Group, 2017-2032 (USD Million)
TABLE 72. Global Intravenous Administration Market Size, by Country, 2017-2032 (USD Million)
TABLE 73. Global Subcutaneous Administration Market Size, by Region, 2017-2032 (USD Million)
TABLE 74. Global Subcutaneous Administration Market Size, by Group, 2017-2032 (USD Million)
TABLE 75. Global Subcutaneous Administration Market Size, by Country, 2017-2032 (USD Million)
TABLE 76. Global Intra-articular Administration Market Size, by Region, 2017-2032 (USD Million)
TABLE 77. Global Intra-articular Administration Market Size, by Group, 2017-2032 (USD Million)
TABLE 78. Global Intra-articular Administration Market Size, by Country, 2017-2032 (USD Million)
TABLE 79. Global Intramuscular Administration Market Size, by Region, 2017-2032 (USD Million)
TABLE 80. Global Intramuscular Administration Market Size, by Group, 2017-2032 (USD Million)
TABLE 81. Global Intramuscular Administration Market Size, by Country, 2017-2032 (USD Million)
TABLE 82. Global Gout Therapeutics Market Size, by Dispensing and Procurement Channel, 2017-2032 (USD Million)
TABLE 83. Global Pharmacy Dispensing Market Size, by Region, 2017-2032 (USD Million)
TABLE 84. Global Pharmacy Dispensing Market Size, by Group, 2017-2032 (USD Million)
TABLE 85. Global Pharmacy Dispensing Market Size, by Country, 2017-2032 (USD Million)
TABLE 86. Global Community and Retail Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 87. Global Community and Retail Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 88. Global Community and Retail Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 89. Global Mail-Order Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 90. Global Mail-Order Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 91. Global Mail-Order Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 92. Global Specialty Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 93. Global Specialty Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 94. Global Specialty Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 95. Global Provider & Institutional Procurement Market Size, by Region, 2017-2032 (USD Million)
TABLE 96. Global Provider & Institutional Procurement Market Size, by Group, 2017-2032 (USD Million)
TABLE 97. Global Provider & Institutional Procurement Market Size, by Country, 2017-2032 (USD Million)
TABLE 98. Global Gout Therapeutics Market Size, by Asset Status, 2017-2032 (USD Million)
TABLE 99. Global Commercially Authorized Assets Market Size, by Region, 2017-2032 (USD Million)
TABLE 100. Global Commercially Authorized Assets Market Size, by Group, 2017-2032 (USD Million)
TABLE 101. Global Commercially Authorized Assets Market Size, by Country, 2017-2032 (USD Million)
TABLE 102. Global Originator and Proprietary Products Market Size, by Region, 2017-2032 (USD Million)
TABLE 103. Global Originator and Proprietary Products Market Size, by Group, 2017-2032 (USD Million)
TABLE 104. Global Originator and Proprietary Products Market Size, by Country, 2017-2032 (USD Million)
TABLE 105. Global Generic Products Market Size, by Region, 2017-2032 (USD Million)
TABLE 106. Global Generic Products Market Size, by Group, 2017-2032 (USD Million)
TABLE 107. Global Generic Products Market Size, by Country, 2017-2032 (USD Million)
TABLE 108. Global Phase I Clinical Assets Market Size, by Region, 2017-2032 (USD Million)
TABLE 109. Global Phase I Clinical Assets Market Size, by Group, 2017-2032 (USD Million)
TABLE 110. Global Phase I Clinical Assets Market Size, by Country, 2017-2032 (USD Million)
TABLE 111. Global Phase II Clinical Assets Market Size, by Region, 2017-2032 (USD Million)
TABLE 112. Global Phase II Clinical Assets Market Size, by Group, 2017-2032 (USD Million)
TABLE 113. Global Phase II Clinical Assets Market Size, by Country, 2017-2032 (USD Million)
TABLE 114. Global Phase III Clinical Assets Market Size, by Region, 2017-2032 (USD Million)
TABLE 115. Global Phase III Clinical Assets Market Size, by Group, 2017-2032 (USD Million)
TABLE 116. Global Phase III Clinical Assets Market Size, by Country, 2017-2032 (USD Million)
TABLE 117. Global Regulatory Review Assets Market Size, by Region, 2017-2032 (USD Million)
TABLE 118. Global Regulatory Review Assets Market Size, by Group, 2017-2032 (USD Million)
TABLE 119. Global Regulatory Review Assets Market Size, by Country, 2017-2032 (USD Million)
TABLE 120. Global Gout Therapeutics Market Size, by Region, 2017-2032 (USD Million)
TABLE 121. North America Gout Therapeutics Market Size, by Region, 2017-2032 (USD Million)
TABLE 122. North America Gout Therapeutics Market Size, by Therapeutic Technology, 2017-2032 (USD Million)
TABLE 123. North America Gout Therapeutics Market Size, by Small-Molecule Therapies, 2017-2032 (USD Million)
TABLE 124. North America Gout Therapeutics Market Size, by Direct-Acting Single-Active Therapies, 2017-2032 (USD Million)
TABLE 125. North America Gout Therapeutics Market Size, by Biologic and Protein Therapies, 2017-2032 (USD Million)
TABLE 126. North America Gout Therapeutics Market Size, by Treatment Line, 2017-2032 (USD Million)
TABLE 127. North America Gout Therapeutics Market Size, by Therapeutic Role, 2017-2032 (USD Million)
TABLE 128. North America Gout Therapeutics Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 129. North America Gout Therapeutics Market Size, by Parenteral Administration, 2017-2032 (USD Million)
TABLE 130. North America Gout Therapeutics Market Size, by Dispensing and Procurement Channel, 2017-2032 (USD Million)
TABLE 131. North America Gout Therapeutics Market Size, by Pharmacy Dispensing, 2017-2032 (USD Million)
TABLE 132. North America Gout Therapeutics Market Size, by Asset Status, 2017-2032 (USD Million)
TABLE 133. North America Gout Therapeutics Market Size, by Commercially Authorized Assets, 2017-2032 (USD Million)
TABLE 134. Europe Gout Therapeutics Market Size, by Region, 2017-2032 (USD Million)
TABLE 135. Europe Gout Therapeutics Market Size, by Therapeutic Technology, 2017-2032 (USD Million)
TABLE 136. Europe Gout Therapeutics Market Size, by Small-Molecule Therapies, 2017-2032 (USD Million)
TABLE 137. Europe Gout Therapeutics Market Size, by Direct-Acting Single-Active Therapies, 2017-2032 (USD Million)
TABLE 138. Europe Gout Therapeutics Market Size, by Biologic and Protein Therapies, 2017-2032 (USD Million)
TABLE 139. Europe Gout Therapeutics Market Size, by Treatment Line, 2017-2032 (USD Million)
TABLE 140. Europe Gout Therapeutics Market Size, by Therapeutic Role, 2017-2032 (USD Million)
TABLE 141. Europe Gout Therapeutics Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 142. Europe Gout Therapeutics Market Size, by Parenteral Administration, 2017-2032 (USD Million)
TABLE 143. Europe Gout Therapeutics Market Size, by Dispensing and Procurement Channel, 2017-2032 (USD Million)
TABLE 144. Europe Gout Therapeutics Market Size, by Pharmacy Dispensing, 2017-2032 (USD Million)
TABLE 145. Europe Gout Therapeutics Market Size, by Asset Status, 2017-2032 (USD Million)
TABLE 146. Europe Gout Therapeutics Market Size, by Commercially Authorized Assets, 2017-2032 (USD Million)
TABLE 147. Asia-Pacific Gout Therapeutics Market Size, by Region, 2017-2032 (USD Million)
TABLE 148. Asia-Pacific Gout Therapeutics Market Size, by Therapeutic Technology, 2017-2032 (USD Million)
TABLE 149. Asia-Pacific Gout Therapeutics Market Size, by Small-Molecule Therapies, 2017-2032 (USD Million)
TABLE 150. Asia-Pacific Gout Therapeutics Market Size, by Direct-Acting Single-Active Therapies, 2017-2032 (USD Million)
TABLE 151. Asia-Pacific Gout Therapeutics Market Size, by Biologic and Protein Therapies, 2017-2032 (USD Million)
TABLE 152. Asia-Pacific Gout Therapeutics Market Size, by Treatment Line, 2017-2032 (USD Million)
TABLE 153. Asia-Pacific Gout Therapeutics Market Size, by Therapeutic Role, 2017-2032 (USD Million)
TABLE 154. Asia-Pacific Gout Therapeutics Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 155. Asia-Pacific Gout Therapeutics Market Size, by Parenteral Administration, 2017-2032 (USD Million)
TABLE 156. Asia-Pacific Gout Therapeutics Market Size, by Dispensing and Procurement Channel, 2017-2032 (USD Million)
TABLE 157. Asia-Pacific Gout Therapeutics Market Size, by Pharmacy Dispensing, 2017-2032 (USD Million)
TABLE 158. Asia-Pacific Gout Therapeutics Market Size, by Asset Status, 2017-2032 (USD Million)
TABLE 159. Asia-Pacific Gout Therapeutics Market Size, by Commercially Authorized Assets, 2017-2032 (USD Million)
TABLE 160. Latin America Gout Therapeutics Market Size, by Region, 2017-2032 (USD Million)
TABLE 161. Latin America Gout Therapeutics Market Size, by Therapeutic Technology, 2017-2032 (USD Million)
TABLE 162. Latin America Gout Therapeutics Market Size, by Small-Molecule Therapies, 2017-2032 (USD Million)
TABLE 163. Latin America Gout Therapeutics Market Size, by Direct-Acting Single-Active Therapies, 2017-2032 (USD Million)
TABLE 164. Latin America Gout Therapeutics Market Size, by Biologic and Protein Therapies, 2017-2032 (USD Million)
TABLE 165. Latin America Gout Therapeutics Market Size, by Treatment Line, 2017-2032 (USD Million)
TABLE 166. Latin America Gout Therapeutics Market Size, by Therapeutic Role, 2017-2032 (USD Million)
TABLE 167. Latin America Gout Therapeutics Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 168. Latin America Gout Therapeutics Market Size, by Parenteral Administration, 2017-2032 (USD Million)
TABLE 169. Latin America Gout Therapeutics Market Size, by Dispensing and Procurement Channel, 2017-2032 (USD Million)
TABLE 170. Latin America Gout Therapeutics Market Size, by Pharmacy Dispensing, 2017-2032 (USD Million)
TABLE 171. Latin America Gout Therapeutics Market Size, by Asset Status, 2017-2032 (USD Million)
TABLE 172. Latin America Gout Therapeutics Market Size, by Commercially Authorized Assets, 2017-2032 (USD Million)
TABLE 173. Middle East Gout Therapeutics Market Size, by Region, 2017-2032 (USD Million)
TABLE 174. Middle East Gout Therapeutics Market Size, by Therapeutic Technology, 2017-2032 (USD Million)
TABLE 175. Middle East Gout Therapeutics Market Size, by Small-Molecule Therapies, 2017-2032 (USD Million)
TABLE 176. Middle East Gout Therapeutics Market Size, by Direct-Acting Single-Active Therapies, 2017-2032 (USD Million)
TABLE 177. Middle East Gout Therapeutics Market Size, by Biologic and Protein Therapies, 2017-2032 (USD Million)
TABLE 178. Middle East Gout Therapeutics Market Size, by Treatment Line, 2017-2032 (USD Million)
TABLE 179. Middle East Gout Therapeutics Market Size, by Therapeutic Role, 2017-2032 (USD Million)
TABLE 180. Middle East Gout Therapeutics Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 181. Middle East Gout Therapeutics Market Size, by Parenteral Administration, 2017-2032 (USD Million)
TABLE 182. Middle East Gout Therapeutics Market Size, by Dispensing and Procurement Channel, 2017-2032 (USD Million)
TABLE 183. Middle East Gout Therapeutics Market Size, by Pharmacy Dispensing, 2017-2032 (USD Million)
TABLE 184. Middle East Gout Therapeutics Market Size, by Asset Status, 2017-2032 (USD Million)
TABLE 185. Middle East Gout Therapeutics Market Size, by Commercially Authorized Assets, 2017-2032 (USD Million)
TABLE 186. Africa Gout Therapeutics Market Size, by Region, 2017-2032 (USD Million)
TABLE 187. Africa Gout Therapeutics Market Size, by Therapeutic Technology, 2017-2032 (USD Million)
TABLE 188. Africa Gout Therapeutics Market Size, by Small-Molecule Therapies, 2017-2032 (USD Million)
TABLE 189. Africa Gout Therapeutics Market Size, by Direct-Acting Single-Active Therapies, 2017-2032 (USD Million)
TABLE 190. Africa Gout Therapeutics Market Size, by Biologic and Protein Therapies, 2017-2032 (USD Million)
TABLE 191. Africa Gout Therapeutics Market Size, by Treatment Line, 2017-2032 (USD Million)
TABLE 192. Africa Gout Therapeutics Market Size, by Therapeutic Role, 2017-2032 (USD Million)
TABLE 193. Africa Gout Therapeutics Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 194. Africa Gout Therapeutics Market Size, by Parenteral Administration, 2017-2032 (USD Million)
TABLE 195. Africa Gout Therapeutics Market Size, by Dispensing and Procurement Channel, 2017-2032 (USD Million)
TABLE 196. Africa Gout Therapeutics Market Size, by Pharmacy Dispensing, 2017-2032 (USD Million)
TABLE 197. Africa Gout Therapeutics Market Size, by Asset Status, 2017-2032 (USD Million)
TABLE 198. Africa Gout Therapeutics Market Size, by Commercially Authorized Assets, 2017-2032 (USD Million)
TABLE 199. Global Gout Therapeutics Market Size, by Group, 2017-2032 (USD Million)
TABLE 200. NATO Gout Therapeutics Market Size, by Group, 2017-2032 (USD Million)
TABLE 201. NATO Gout Therapeutics Market Size, by Therapeutic Technology, 2017-2032 (USD Million)
TABLE 202. NATO Gout Therapeutics Market Size, by Small-Molecule Therapies, 2017-2032 (USD Million)
TABLE 203. NATO Gout Therapeutics Market Size, by Direct-Acting Single-Active Therapies, 2017-2032 (USD Million)
TABLE 204. NATO Gout Therapeutics Market Size, by Biologic and Protein Therapies, 2017-2032 (USD Million)
TABLE 205. NATO Gout Therapeutics Market Size, by Treatment Line, 2017-2032 (USD Million)
TABLE 206. NATO Gout Therapeutics Market Size, by Therapeutic Role, 2017-2032 (USD Million)
TABLE 207. NATO Gout Therapeutics Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 208. NATO Gout Therapeutics Market Size, by Parenteral Administration, 2017-2032 (USD Million)
TABLE 209. NATO Gout Therapeutics Market Size, by Dispensing and Procurement Channel, 2017-2032 (USD Million)
TABLE 210. NATO Gout Therapeutics Market Size, by Pharmacy Dispensing, 2017-2032 (USD Million)
TABLE 211. NATO Gout Therapeutics Market Size, by Asset Status, 2017-2032 (USD Million)
TABLE 212. NATO Gout Therapeutics Market Size, by Commercially Authorized Assets, 2017-2032 (USD Million)
TABLE 213. G7 Gout Therapeutics Market Size, by Group, 2017-2032 (USD Million)
TABLE 214. G7 Gout Therapeutics Market Size, by Therapeutic Technology, 2017-2032 (USD Million)
TABLE 215. G7 Gout Therapeutics Market Size, by Small-Molecule Therapies, 2017-2032 (USD Million)
TABLE 216. G7 Gout Therapeutics Market Size, by Direct-Acting Single-Active Therapies, 2017-2032 (USD Million)
TABLE 217. G7 Gout Therapeutics Market Size, by Biologic and Protein Therapies, 2017-2032 (USD Million)
TABLE 218. G7 Gout Therapeutics Market Size, by Treatment Line, 2017-2032 (USD Million)
TABLE 219. G7 Gout Therapeutics Market Size, by Therapeutic Role, 2017-2032 (USD Million)
TABLE 220. G7 Gout Therapeutics Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 221. G7 Gout Therapeutics Market Size, by Parenteral Administration, 2017-2032 (USD Million)
TABLE 222. G7 Gout Therapeutics Market Size, by Dispensing and Procurement Channel, 2017-2032 (USD Million)
TABLE 223. G7 Gout Therapeutics Market Size, by Pharmacy Dispensing, 2017-2032 (USD Million)
TABLE 224. G7 Gout Therapeutics Market Size, by Asset Status, 2017-2032 (USD Million)
TABLE 225. G7 Gout Therapeutics Market Size, by Commercially Authorized Assets, 2017-2032 (USD Million)
TABLE 226. European Union Gout Therapeutics Market Size, by Group, 2017-2032 (USD Million)
TABLE 227. European Union Gout Therapeutics Market Size, by Therapeutic Technology, 2017-2032 (USD Million)
TABLE 228. European Union Gout Therapeutics Market Size, by Small-Molecule Therapies, 2017-2032 (USD Million)
TABLE 229. European Union Gout Therapeutics Market Size, by Direct-Acting Single-Active Therapies, 2017-2032 (USD Million)
TABLE 230. European Union Gout Therapeutics Market Size, by Biologic and Protein Therapies, 2017-2032 (USD Million)
TABLE 231. European Union Gout Therapeutics Market Size, by Treatment Line, 2017-2032 (USD Million)
TABLE 232. European Union Gout Therapeutics Market Size, by Therapeutic Role, 2017-2032 (USD Million)
TABLE 233. European Union Gout Therapeutics Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 234. European Union Gout Therapeutics Market Size, by Parenteral Administration, 2017-2032 (USD Million)
TABLE 235. European Union Gout Therapeutics Market Size, by Dispensing and Procurement Channel, 2017-2032 (USD Million)
TABLE 236. European Union Gout Therapeutics Market Size, by Pharmacy Dispensing, 2017-2032 (USD Million)
TABLE 237. European Union Gout Therapeutics Market Size, by Asset Status, 2017-2032 (USD Million)
TABLE 238. European Union Gout Therapeutics Market Size, by Commercially Authorized Assets, 2017-2032 (USD Million)
TABLE 239. BRICS Gout Therapeutics Market Size, by Group, 2017-2032 (USD Million)
TABLE 240. BRICS Gout Therapeutics Market Size, by Therapeutic Technology, 2017-2032 (USD Million)
TABLE 241. BRICS Gout Therapeutics Market Size, by Small-Molecule Therapies, 2017-2032 (USD Million)
TABLE 242. BRICS Gout Therapeutics Market Size, by Direct-Acting Single-Active Therapies, 2017-2032 (USD Million)
TABLE 243. BRICS Gout Therapeutics Market Size, by Biologic and Protein Therapies, 2017-2032 (USD Million)
TABLE 244. BRICS Gout Therapeutics Market Size, by Treatment Line, 2017-2032 (USD Million)
TABLE 245. BRICS Gout Therapeutics Market Size, by Therapeutic Role, 2017-2032 (USD Million)
TABLE 246. BRICS Gout Therapeutics Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 247. BRICS Gout Therapeutics Market Size, by Parenteral Administration, 2017-2032 (USD Million)
TABLE 248. BRICS Gout Therapeutics Market Size, by Dispensing and Procurement Channel, 2017-2032 (USD Million)
TABLE 249. BRICS Gout Therapeutics Market Size, by Pharmacy Dispensing, 2017-2032 (USD Million)
TABLE 250. BRICS Gout Therapeutics Market Size, by Asset Status, 2017-2032 (USD Million)
TABLE 251. BRICS Gout Therapeutics Market Size, by Commercially Authorized Assets, 2017-2032 (USD Million)
TABLE 252. ASEAN Gout Therapeutics Market Size, by Group, 2017-2032 (USD Million)
TABLE 253. ASEAN Gout Therapeutics Market Size, by Therapeutic Technology, 2017-2032 (USD Million)
TABLE 254. ASEAN Gout Therapeutics Market Size, by Small-Molecule Therapies, 2017-2032 (USD Million)
TABLE 255. ASEAN Gout Therapeutics Market Size, by Direct-Acting Single-Active Therapies, 2017-2032 (USD Million)
TABLE 256. ASEAN Gout Therapeutics Market Size, by Biologic and Protein Therapies, 2017-2032 (USD Million)
TABLE 257. ASEAN Gout Therapeutics Market Size, by Treatment Line, 2017-2032 (USD Million)
TABLE 258. ASEAN Gout Therapeutics Market Size, by Therapeutic Role, 2017-2032 (USD Million)
TABLE 259. ASEAN Gout Therapeutics Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 260. ASEAN Gout Therapeutics Market Size, by Parenteral Administration, 2017-2032 (USD Million)
TABLE 261. ASEAN Gout Therapeutics Market Size, by Dispensing and Procurement Channel, 2017-2032 (USD Million)
TABLE 262. ASEAN Gout Therapeutics Market Size, by Pharmacy Dispensing, 2017-2032 (USD Million)
TABLE 263. ASEAN Gout Therapeutics Market Size, by Asset Status, 2017-2032 (USD Million)
TABLE 264. ASEAN Gout Therapeutics Market Size, by Commercially Authorized Assets, 2017-2032 (USD Million)
TABLE 265. GCC Gout Therapeutics Market Size, by Group, 2017-2032 (USD Million)
TABLE 266. GCC Gout Therapeutics Market Size, by Therapeutic Technology, 2017-2032 (USD Million)
TABLE 267. GCC Gout Therapeutics Market Size, by Small-Molecule Therapies, 2017-2032 (USD Million)
TABLE 268. GCC Gout Therapeutics Market Size, by Direct-Acting Single-Active Therapies, 2017-2032 (USD Million)
TABLE 269. GCC Gout Therapeutics Market Size, by Biologic and Protein Therapies, 2017-2032 (USD Million)
TABLE 270. GCC Gout Therapeutics Market Size, by Treatment Line, 2017-2032 (USD Million)
TABLE 271. GCC Gout Therapeutics Market Size, by Therapeutic Role, 2017-2032 (USD Million)
TABLE 272. GCC Gout Therapeutics Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 273. GCC Gout Therapeutics Market Size, by Parenteral Administration, 2017-2032 (USD Million)
TABLE 274. GCC Gout Therapeutics Market Size, by Dispensing and Procurement Channel, 2017-2032 (USD Million)
TABLE 275. GCC Gout Therapeutics Market Size, by Pharmacy Dispensing, 2017-2032 (USD Million)
TABLE 276. GCC Gout Therapeutics Market Size, by Asset Status, 2017-2032 (USD Million)
TABLE 277. GCC Gout Therapeutics Market Size, by Commercially Authorized Assets, 2017-2032 (USD Million)
TABLE 278. Global Gout Therapeutics Market Size, by Country, 2017-2032 (USD Million)
TABLE 279. United States Gout Therapeutics Market Size, 2017-2032 (USD Million)
TABLE 280. United States Gout Therapeutics Market Size, by Therapeutic Technology, 2017-2032 (USD Million)
TABLE 281. United States Gout Therapeutics Market Size, by Small-Molecule Therapies, 2017-2032 (USD Million)
TABLE 282. United States Gout Therapeutics Market Size, by Direct-Acting Single-Active Therapies, 2017-2032 (USD Million)
TABLE 283. United States Gout Therapeutics Market Size, by Biologic and Protein Therapies, 2017-2032 (USD Million)
TABLE 284. United States Gout Therapeutics Market Size, by Treatment Line, 2017-2032 (USD Million)
TABLE 285. United States Gout Therapeutics Market Size, by Therapeutic Role, 2017-2032 (USD Million)
TABLE 286. United States Gout Therapeutics Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 287. United States Gout Therapeutics Market Size, by Parenteral Administration, 2017-2032 (USD Million)
TABLE 288. United States Gout Therapeutics Market Size, by Dispensing and Procurement Channel, 2017-2032 (USD Million)
TABLE 289. United States Gout Therapeutics Market Size, by Pharmacy Dispensing, 2017-2032 (USD Million)
TABLE 290. United States Gout Therapeutics Market Size, by Asset Status, 2017-2032 (USD Million)
TABLE 291. United States Gout Therapeutics Market Size, by Commercially Authorized Assets, 2017-2032 (USD Million)
TABLE 292. Japan Gout Therapeutics Market Size, 2017-2032 (USD Million)
TABLE 293. Japan Gout Therapeutics Market Size, by Therapeutic Technology, 2017-2032 (USD Million)
TABLE 294. Japan Gout Therapeutics Market Size, by Small-Molecule Therapies, 2017-2032 (USD Million)
TABLE 295. Japan Gout Therapeutics Market Size, by Direct-Acting Single-Active Therapies, 2017-2032 (USD Million)
TABLE 296. Japan Gout Therapeutics Market Size, by Biologic and Protein Therapies, 2017-2032 (USD Million)
TABLE 297. Japan Gout Therapeutics Market Size, by Treatment Line, 2017-2032 (USD Million)
TABLE 298. Japan Gout Therapeutics Market Size, by Therapeutic Role, 2017-2032 (USD Million)
TABLE 299. Japan Gout Therapeutics Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 300. Japan Gout Therapeutics Market Size, by Parenteral Administration, 2017-2032 (USD Million)
TABLE 301. Japan Gout Therapeutics Market Size, by Dispensing and Procurement Channel, 2017-2032 (USD Million)
TABLE 302. Japan Gout Therapeutics Market Size, by Pharmacy Dispensing, 2017-2032 (USD Million)
TABLE 303. Japan Gout Therapeutics Market Size, by Asset Status, 2017-2032 (USD Million)
TABLE 304. Japan Gout Therapeutics Market Size, by Commercially Authorized Assets, 2017-2032 (USD Million)
TABLE 305. China Gout Therapeutics Market Size, 2017-2032 (USD Million)
TABLE 306. China Gout Therapeutics Market Size, by Therapeutic Technology, 2017-2032 (USD Million)
TABLE 307. China Gout Therapeutics Market Size, by Small-Molecule Therapies, 2017-2032 (USD Million)
TABLE 308. China Gout Therapeutics Market Size, by Direct-Acting Single-Active Therapies, 2017-2032 (USD Million)
TABLE 309. China Gout Therapeutics Market Size, by Biologic and Protein Therapies, 2017-2032 (USD Million)
TABLE 310. China Gout Therapeutics Market Size, by Treatment Line, 2017-2032 (USD Million)
TABLE 311. China Gout Therapeutics Market Size, by Therapeutic Role, 2017-2032 (USD Million)
TABLE 312. China Gout Therapeutics Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 313. China Gout Therapeutics Market Size, by Parenteral Administration, 2017-2032 (USD Million)
TABLE 314. China Gout Therapeutics Market Size, by Dispensing and Procurement Channel, 2017-2032 (USD Million)
TABLE 315. China Gout Therapeutics Market Size, by Pharmacy Dispensing, 2017-2032 (USD Million)
TABLE 316. China Gout Therapeutics Market Size, by Asset Status, 2017-2032 (USD Million)
TABLE 317. China Gout Therapeutics Market Size, by Commercially Authorized Assets, 2017-2032 (USD Million)
TABLE 318. Germany Gout Therapeutics Market Size, 2017-2032 (USD Million)
TABLE 319. Germany Gout Therapeutics Market Size, by Therapeutic Technology, 2017-2032 (USD Million)
TABLE 320. Germany Gout Therapeutics Market Size, by Small-Molecule Therapies, 2017-2032 (USD Million)
TABLE 321. Germany Gout Therapeutics Market Size, by Direct-Acting Single-Active Therapies, 2017-2032 (USD Million)
TABLE 322. Germany Gout Therapeutics Market Size, by Biologic and Protein Therapies, 2017-2032 (USD Million)
TABLE 323. Germany Gout Therapeutics Market Size, by Treatment Line, 2017-2032 (USD Million)
TABLE 324. Germany Gout Therapeutics Market Size, by Therapeutic Role, 2017-2032 (USD Million)
TABLE 325. Germany Gout Therapeutics Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 326. Germany Gout Therapeutics Market Size, by Parenteral Administration, 2017-2032 (USD Million)
TABLE 327. Germany Gout Therapeutics Market Size, by Dispensing and Procurement Channel, 2017-2032 (USD Million)
TABLE 328. Germany Gout Therapeutics Market Size, by Pharmacy Dispensing, 2017-2032 (USD Million)
TABLE 329. Germany Gout Therapeutics Market Size, by Asset Status, 2017-2032 (USD Million)
TABLE 330. Germany Gout Therapeutics Market Size, by Commercially Authorized Assets, 2017-2032 (USD Million)
TABLE 331. United Kingdom Gout Therapeutics Market Size, 2017-2032 (USD Million)
TABLE 332. United Kingdom Gout Therapeutics Market Size, by Therapeutic Technology, 2017-2032 (USD Million)
TABLE 333. United Kingd

Companies Mentioned

  • Amgen Inc.
  • Takeda Pharmaceutical Company Limited
  • Teijin Pharma Limited
  • Menarini Group
  • Fuji Yakuhin Co., Ltd.
  • Eisai Co., Ltd.
  • Novartis AG
  • Hikma Pharmaceuticals PLC
  • Scilex Holding Company
  • Swedish Orphan Biovitrum AB
  • LG Chem, Ltd.
  • JW Pharmaceutical
  • Crystalys Therapeutics, Inc.
  • Sun Pharmaceutical Industries Limited
  • Aurobindo Pharma Limited
  • Dr. Reddy's Laboratories Limited
  • Innovent Biologics, Inc.
  • Atom Therapeutics Co., Ltd.
  • Shanton Pharma Holdings Limited
  • Sanwa Kagaku Kenkyusho Co., Ltd.
  • TOA EIYO LTD.
  • Mochida Pharmaceutical Co., Ltd.
  • Kaken Pharmaceutical Co., Ltd.
  • Viatris Inc.
  • Apotex Inc.
  • Rising Pharma Holdings, Inc.
  • Alembic Pharmaceuticals Limited
  • KRKA, d. d., Novo mesto
  • Laboratoires Mayoly Spindler
  • Jiangsu Hengrui Pharmaceuticals Co., Ltd.
  • Protalix BioTherapeutics, Inc.
  • Olatec Therapeutics LLC
  • 3SBio Inc.
  • Changchun GeneScience Pharmaceutical Co., Ltd.
  • BioRay Biopharmaceutical Co., Ltd.
  • China Medical System Holdings Limited
  • Shanghai Institute of Biological Products Co., Ltd.
  • Innorna Co., Ltd.
  • ANI Pharmaceuticals, Inc.

Table Information

Report AttributeDetails
No. of Pages193
PublishedSeptember 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 3.8 Billion
Forecasted Market Value ( USD ) by 2032 $ 7.36 Billion
Compound Annual Growth Rate11.4%
Regions CoveredGlobal
No. of Companies Mentioned39

Related Topics

Related Reports

Gout Therapeutics - Global Strategic Business Report - Product Image

Gout Therapeutics - Global Strategic Business Report

  • Report
  • 279 Pages
  • Global
From
Gout Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, & Forecast, 2020-2030 - Product Image

Gout Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, & Forecast, 2020-2030

  • Report
  • 180 Pages
  • Global
From
Global Chronic Gout Market: Focus on Drug Class, Disease Type, Distribution Channel, Country, and Region - Analysis and Forecast, 2026-2036 - Product Image

Global Chronic Gout Market: Focus on Drug Class, Disease Type, Distribution Channel, Country, and Region - Analysis and Forecast, 2026-2036

  • Report
  • Global
From
Gout Therapeutics Market Report 2026 - Product Image

Gout Therapeutics Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Gout Disease Treatment Market Outlook 2026-2034: Market Share, and Growth Analysis - Product Image

Gout Disease Treatment Market Outlook 2026-2034: Market Share, and Growth Analysis

  • Report
  • 160 Pages
  • Global
From

About the Gout Drug Market

The Gout Drug market is a subset of the Immune Disorders Drugs market, which includes treatments for a variety of conditions related to the immune system. Gout drugs are used to reduce the inflammation and pain associated with gout, a type of arthritis caused by the buildup of uric acid in the joints. These drugs can be taken orally or injected directly into the affected joint. Commonly prescribed gout drugs include non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and colchicine. Gout drugs are typically prescribed by a doctor and are available in both generic and brand-name forms. The cost of these drugs can vary depending on the type of drug, the dosage, and the form in which it is taken. Some companies in the Gout Drug market include Pfizer, Merck, Novartis, and Sanofi. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.